Translational Psychiatry
July 20, 2026
Yong-Yu Yin, Si-Rui Sun, Hui-Ying Zhang et al.
Ketamine, a non-competitive N-methyl-D-aspartate acid (NMDA) receptor antagonist, produces rapid and sustained antidepressant actions, but the underlying molecular mechanism remains unclear. The CX 3 CL1/CX 3 CR1 signaling is closely related to mood disorders, and this study aims to investigate its role in ketamine’s antidepressant actions. We pharmacologically (AZD8797, a selective CX 3 CR1...
J Psychopharmacol
June 28, 2026
Yingjie Du, Xiangting Zhao, Yishan Yao et al.
BACKGROUND: Posttraumatic stress disorder (PTSD) and major depressive disorder are often comorbid in humans. Psilocybin reportedly has beneficial therapeutic effects on depression, possibly by promoting neuroplasticity. PTSD is associated with the dysregulation of neuroplasticity in the hippocampus and medial prefrontal cortex (mPFC). We hypothesized that psilocybin might reduce fear memory by...
ACS Chemical Neuroscience
July 3, 2024
Yue Zhang, Hui Ma, Yafan Bai et al.
25 citations
Chronic neuropathic pain and comorbid depression syndrome (CDS) is a major worldwide health problem that affects the quality of life of patients and imposes a tremendous socioeconomic burden. More than half of patients with chronic neuropathic pain also suffer from moderate or severe depression. Due to the complex pathogenesis of CDS, there are no effective therapeutic drugs available. The lack...
Journal of Psychopharmacology
April 28, 2024
Xiangting Zhao, Yingjie Du, Yishan Yao et al.
53 citations
Background: Psilocybin offers new hope for treating mood disorders due to its rapid and sustained antidepressant effects, as standard medications require weeks or months to exert their effects. However, the mechanisms underlying this action of psilocybin have not been identified. Aims: To investigate whether psilocybin has rapid and sustained antidepressant-like effects in mice and investigate...
Chinese medical journal
December 20, 2023
Yingjie Du, Yunfeng Li, Xiangting Zhao et al.
71 citations
Posttraumatic stress disorder (PTSD) and depression are highly comorbid. Psilocybin exerts substantial therapeutic effects on depression by promoting neuroplasticity. Fear extinction is a key process in the mechanism of first-line exposure-based therapies for PTSD. We hypothesized that psilocybin would facilitate fear extinction by promoting hippocampal neuroplasticity. First, we assessed the...